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EXPOSURE OF PRESCRIBED CHINESE MEDICATIONS AMONG ELDERLY 
PATIENTS TAKING DIGOXIN  
Lin HW1, Yu IW2, Wu MP1, Tsai HH1 
1China Medical University, Taichung, Taiwan, 2China Medical University Hospital, Taichung, Taiwan  
OBJECTIVES: Those elderly patients are vulnerable to digoxin toxicity due to 
their diminished organ functions and tendency to occur drug interactions with 
digoxin. The aim of this research was to describe the exposure patterns of 
prescribed Chinese Medications (CM) and its associated factors among elderly 
patients taking digoxin. METHODS: A retrospective population-based cohort 
study was conducted Longitudinal Health Insurance databases in Taiwan. Those 
elderly patients being prescribed with digoxin in outpatient settings during 2006 
were evaluated for their concurrent use of prescribed CM (prevalence, incidence 
[excluding concurrent use of CM six month prior], duration). After 1 to 4 
randomly matching for those CM-digoxin users and digoxin-along users, the 
multivariate logistic regression was performed to explore factors associated with 
concomitant CM-digoxin use and exposure to specific potential interactions. 
RESULTS: Of 185,076 elderly in 2006 in Taiwan, 6,364 (3.4%) used digoxin and 754 
(0.4%) were CM-digoxin users. Within one-year following-up, the prevalence and 
incidence of concomitant CM use among digoxin elderly users were 13.4% and 
7.1%, respectively. The average durations were 190.7±136.7 days for digoxin 
elderly users, 30.8±49.6 days for prevalent CM-digoxin users, and 17.25±23.9 days 
for incident CM-digoxin users. While other factors were not statistically 
significant associated with incident CM-digoxin use, patients with coronary 
heart diseases (CAD) increased 218% likelihood of incident CM-digoxin use. 
Those with CAD and BPH and used more health care resources tended to use 
specific CM with digoxin. CONCLUSIONS: With substantial amount of CM-
digoxin users among the elderly, further study is needed to explore the impact of 
patient outcomes on concurrent use of CM with digoxin.  
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EPIDEMIOLOGY AND MORTALITY OF VENOUS THROMBOEMBOLISM ACROSS 
PATIENT POPULATIONS: A SYSTEMATIC LITERATURE REVIEW  
Liu X1, Phatak H2, Dillon R3, Mitchell SA3 
1Pfizer, Inc., New York, NY, USA, 2Bristol-Myers Squibb Company, Princeton, NJ, USA, 3Abacus 
International, Bicester, UK  
OBJECTIVES: Venous thromboembolism (VTE) is a pathological condition 
inclusive of deep vein thrombosis (DVT) and pulmonary embolism (PE). A 
systematic review was conducted to summarize the global epidemiological 
burden and mortality of primary/recurrent VTE events across patient 
populations. METHODS: Eligible studies (both full publications and abstracts) 
were identified from an exhaustive, systematic database review. Outcomes of 
interest included incidence/prevalence of primary/recurrent VTE, mortality and 
associated risk factors. RESULTS: The estimated annual incidence rate of DVT 
and PE in the US, Europe and Asia was reported at 0.21-1.48 per 1,000 person-
years, with a prevalence of 0.2-0.66%. In the US, prevalence is estimated to 
increase from the current estimate of 0.42% to 0.57% by 2050, driven by 
population growth and increased detection. Although there was a paucity of 
Asian data, published results suggest a lower prevalence compared with Western 
countries. Risk factors for VTE include increased age, male sex, ethnicity, 
surgery, cancer, initial event type and pharmacology. VTE recurrence is 
dependent on both the initial event type and/or the presence of VTE risk factors. 
The risk of recurrence peaks 6 to 12 months following the primary event, with 5-
year cumulative recurrence estimated at ~28%. VTE-related mortality in the US 
and Europe was reported to occur in up to 370,000 patients annually and is 
estimated to account for 10% of all in-hospital deaths. The level of PE-related 
mortality was up to 60%, was dependent on underlying risk factors, and was 
markedly higher compared with DVT-related mortality. CONCLUSIONS: VTE is 
particularly prevalent in the elderly, active cancer and surgical populations with 
major additional risk factors including sex and ethnicity. VTE carries significant 
levels of mortality with the highest levels reported in care based versus 
community setting. Increased population growth and aging population 
demographic coupled with improved detection will result in an increasing health 
care burden.  
 
PCV6  
ASSESSMENT OF DRUG RELATED PROBLEMS (DRP) IN PRESCRIPTIONS 
RECEIVED BY PATIENTS SUFFERING FROM CHRONIC DISEASES DWELLING IN A 
SOUTH INDIAN RURAL COMMUNITY  
Adepu R, Adusumilli PK, Jaidev kumar BR 
JSS University, Mysore, India  
OBJECTIVES: To assess the incidence, prevalence and cost implications of drug 
related problems in patients with chronic diseases dwelling in a local 
community METHODS: The present study was a prospective observational study 
conducted in a South Indian city residential area. Institutional ethics committee 
has approved the study. The research pharmacist recorded the details of patients 
with chronic diseases through house visits and reviewed the prescriptions of the 
enrolled patients for drug related problems with their consent. Cipolle’s 
classification was used to assess the type of DRPs. Prevalence, severity level and 
significance of DRP’s was also assessed and net societal cost burden due to the 
DRPs was also calculated. RESULTS: During the six months study period, 480 
houses were surveyed and identified 190 patients (Male: 80 and Female:110) with 
chronic diseases. A total of 80 DRPs were identified in the prescriptions with an 
incidence rate of 42%. Types of DRP were Medication errors/ non compliance (17), 
untreated indications (15) and Drug interactions (14) and ADRs (8) were the most 
commonly observed DRPs. As per the severity, 9 DRPs were major, 32 DRPs were 
moderate and 39 DRP were minor and clinically non significant. The net societal 
cost burden due to DRPs was calculated as Rs.72,04,000/-. CONCLUSIONS: The 
study concludes that, incidence of DRPs in patients with chronic diseases is 
about 42% and the net societal cost burden due to DRPs was found 
Rs.72,04,000.00.  
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DISTRIBUTION OF LEFT VENTRICLE EJECTION FRACTION (LVEF), PATIENT 
ATTRIBUTES, AND MEDICATION USE IN HEART FAILURE PATIENTS IN A US 
ELECTRONIC MEDICAL RECORD DATABASE  
Park J1, Lin J2, Tian H1, Goodman M2, McAdam-Marx C2, Kahler K1 
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2University of Utah, Salt Lake 
City, UT, USA  
OBJECTIVES: To compare real-world characteristics and medication use in heart 
failure (HF) patients with REF, Reduced Ejection Fraction (EF <45%) versus PEF, 
Preserved Ejection Fraction (EF ≥45%). METHODS: Using the General Electric, 
electronic medical record database (GE-EMR), patients with a diagnosis of 
congestive heart failure (CHF) prior to the index data, which was defined as the 
first date of ejection fraction test (index date) between January 1, 2005 and 
December 31, 2009, were identified. Additional inclusion criteria include age ≥18 
years and availability of 12 months pre- and post- index date data. Patient 
demographics, clinical profile, and medication use patterns in the 12 months 
post-index period were compared between the patients with HF- REF and HF-
PEF. Bivariate analyses were conducted to determine differences between 
groups. RESULTS: Of 15,457 patients who met inclusion criteria, 9,884 (64%) had 
HF-PEF. PEF patients were older (71.4 vs. 69.1 years; p<0.0001), more likely to be 
female (55.5% vs. 32.7%; p<0.0001), obese (2.7% vs. 1.4%; p=0.0009) and diagnosed 
with hypertension (53.3% vs. 42.7%; p=0.0013), diabetes (30.0% vs. 27.8%; p=0.04), 
atrial fibrillation (25.2% vs. 20.5%; p<0.0001), lipid disorders (47.3% vs. 43.8%; 
p=0.0079), and other cardiovascular disease (13.3% vs. 11.7%;p=0.04). Compared 
to REF, PEF patients are less likely to be treated with ACEi (27.9% vs. 40.2%; 
p<0.0001), loop diuretics (46.0% vs. 51.8%; p<0.0001), alpha-beta blockers (13.7 vs. 
41.1 %; p<0.0001) and Spironolactone (7.40 vs. 16.4%; p<0.0001) while they are 
more likely to be treated with calcium channel blockers (21.8% vs. 12.7%; 
p<0.0001). CONCLUSIONS: Compared to patients with REF, PEF patients are more 
likely to be older and have cardiovascular/metabolic comorbid conditions. 
Medication use patterns suggest that compared to REF patients, PEF patients are 
less likely to be treated with medications with HF indications and more likely to 
be treated to control their underlying hypertension.  
 
PCV8  
DOES ATRIAL FIBRILLATION CONFER GREATER RISK FOR ACUTE CORONARY 
SYNDROME?  
Crivera C1, Schein JR1, Heubner BM2, Damaraju CV1, Herzog CA2 
1Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Minneapolis Medical Research Foundation, 
Minneapolis, MN, USA  
OBJECTIVES: In large observational studies, eight to 12% of patients with acute 
coronary syndromes (ACS) have prevalent atrial fibrillation (AF). However, the 
determinants of subsequent ACS development in the patient population with 
incident AF have not been well described. We hypothesized that risk factors 
present at the onset of AF might identify individuals at increased risk for ACS 
over the following three years. METHODS: The 5% Medicare database was used 
to identify 18,445 patients (no ESRD, age 65+) who had new-onset AF in 2006 and 
no AF or ACS in the year prior. Medicare claims were used to identify patients 
hospitalized with any acute myocardial infarction (AMI, ICD-9-CM diagnosis code 
410, 410.X, 410.X0, or 410.X1) and unstable angina (code 411). Cumulative 
incidence was calculated for the competing risks of ACS and death. RESULTS: 
Patients who had incident AF (n=18,445) in 2006 and no ACS in the previous 12 
months had multiple comorbidities. The most prevalent comorbidities were 
hypertension (67%), coronary artery disease (33%), diabetes mellitus (26%), 
dysrhythmia (26%), dyslipidemia (24%), other cardiovascular disease (23%), heart 
failure (21%), chronic obstructive pulmonary disease (18%), and cerebrovascular 
accident/TIA (15%). Overall, 8% of new-onset AF patients experienced ACS within 
three years. The cumulative risk of developing ACS was higher in patients with 
comorbidities. For example, 6% of patients with either diabetes, HF or CAD 
developed ACS within one year; this rate increased to 11% by three years. The 
risk of developing ACS at three years increased by 5% relative to year one. 
CONCLUSIONS: Patients with new-onset AF are at risk for atherothrombotic 
adverse outcomes such as ACS in addition to their recognized increased risk for 
thromboembolic stroke. Approximately one out of every 12 patients (8%) with 
newly diagnosed AF developed ACS within three years; this risk was 
substantially increased by comorbid diabetes, heart failure, or coronary disease.  
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DIABETES AND SEVERITY OF CORONARY ARTERY DISEASE: ASSESSMENT OF 
CLINICAL, EPIDEMIOLOGIC, AND ANGIOGRAPHIC CHARACTERISTICS  
Shah BS1, Deshpande SS2 
1KSV University, Gandhinagar, India, 2KB Institute of Pharmaceutical Education and Research 
(KBIPER), Gandhinagar, India  
OBJECTIVES: Evaluate and compare clinical characteristics, risk factors,  
and disease severity (on angiographic findings) among diabetic and non-diabetic 
patients with coronary artery disease (CAD). METHODS: Observational study; 
consecutive patients admitted in ICU at tertiary care hospital, underwent 
coronary angiography (CAG) and diagnosed as CAD using standard definitions 
(acute coronary syndrome [ACS] i.e. myocardial infarction [MI], or unstable 
angina [UA]; or chronic stable angina [CSA]). The data included demographic 
information, risk factors for CAD, and angiographic findings. The linear stepwise 
regression was used to assess predictor of severity (more sever [double vessel 
disease, DVD or triple vessel disease, TVD] versus less sever [minimal/non-
critical disease or single vessel disease, SVD]) of CAD. The independent variables 
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studied include age (<45 vs. ≥45 years), hypertension, diabetes, congestive heart 
failure (CHF, history of heart failure or ejection fraction [EF] ≤40%), gender,  
prior MI, final diagnosis, and MI type. RESULTS: Of 1166 consecutive patients, 
1073 underwent CAG, considered eligible: normal coronaries, 113 (10.5%); leaving 
960 patients with CAD (MI [289, 30.1%], UA [604, 62.9%], Undetermined ACS [32, 
3.3%], CSA [35, 3.7%]); 30% patients were diabetic. Proportion of hypertensive 
patients was significantly higher among diabetics (57.7% vs. 34.9% non-diabetics, 
P<0.001). The presence of CHF in the diabetic as well as non-diabetic patients 
was similar. For all patients with CAD, around 40% had SVD on CAG; for 
diabetics, 35% patients had TVD whereas the proportion was only 24% among 
non-diabetics. In the linear stepwise regression, age ≥45 years, presence of CHF 
and diabetes showed significant positive correlation with the severity of CAD 
(p<0.05). CONCLUSIONS: Clustering of several cardiovascular risk factors at 
presentation may lead to the worse prognosis in patients with CAD from India. 
Findings from this study ascertain more severe angiographic findings in diabetic 
patients than that in non-diabetic controls regarding the severity of CAD.  
 
PCV10  
RACIAL VARIATION IN HEART FAILURE COMORBIDITIES AND THERAPY USE IN 
A MEDICAID POPULATION  
Shaya FT1, Breunig IM1, Mehra MR2 
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Harvard Medical School, 
Boston, MA, USA  
OBJECTIVES: To explore the association between race, comorbidities, and 
therapy use among patients with heart failure (HF) in a contemporary Medicaid 
population. METHODS: Medical/prescription/enrollment records from the 
Maryland State Medicaid Managed Care Organization/Fee-for-services, ages 18-
64, non-dual enrolled, with HF diagnosis between July 1, 2005 to December 31, 
2009, followed at least 3 months. Diagnosis for HF defined as earliest encounter 
claim that included ICD-9 code 428.xx. Comorbidity diagnosis determined 
between earliest claim and within three months post-HF diagnosis. First-line 
therapies ascertained using pharmacy claims with first-date-of-service between 
HF diagnosis and the end of follow up. Variation in comorbidities and therapy 
use across race/ethnicity is described. RESULTS: Among 15,764 HF patients, 60% 
(n=9,388) were black, 33% (n=5,158) white, 6% (n=919) other, 2% (n=299) Hispanic. 
Over half were female (55%); 72% older than 44 years. Prevalence in 
race/ethnicity: COPD (40% white, 22% black, 20% other, 11% Hispanic; p<0.001), 
stroke (20-22%; p=0.17), renal dysfunction (38% Hispanic, 30% black, 27%other, 
22% white; p<0.001), diabetes (38-42%; p=0.04), psychological disorder (65% white, 
52% black, 46% other, 37% Hispanic; p<0.001), hyperlipidemia (44% white, 39% 
Hispanic, 31% other, 33% black; p<0.001), chronic ischemic heart disease (47% 
white, 41% black/Hispanic/other; p<0.001), hypertension (76% black, 72% 
Hispanic, 68% white, 67% other; p<0.001), other cardiovascular disease (76-80%; 
p=0.17). Excluding other cardiovascular disease, the median number of comorbid 
conditions was 3 in each race/ethnicity. Among black, white, Hispanic and other, 
only 5.8%, 4.4%, 9.0%, and 7.3% had zero comorbidities, and 14.2%, 11.4%, 12.4%, 
15.8% had only one comorbidity, respectively. Hispanics (53%) were less likely 
than blacks (62%), whites (61%), or others (57%) to be prescribed ACE-
inhibitor/ARB, beta-blockers, aldosterone antagonists, and/or other 
cardiovascular drugs including combination nitrates/hydralazine (p<0.001). 
CONCLUSIONS: Whites were most likely to be diagnosed with COPD, 
psychological disorders, hyperlipidemia, and chronic ischemic heart disease. 
Hypertension was most likely among Blacks, and renal dysfunction most likely 
among Hispanics.  
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COMORBIDITY BURDEN AMONG HEART FAILURE PATIENTS IN A MEDICAID 
POPULATION  
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OBJECTIVES: Increasing prevalence of heart failure, increasing enrollment in 
state programs, sparse literature on population-based heart failure studies, and 
the associations between lower socioeconomic status and increased comorbidity 
burden necessitate an examination of the prevalence of HF comorbidities in a 
contemporary Medicaid population. METHODS: Medical/prescription/enrollment 
records from the Maryland State Medicaid Managed Care Organization/Fee-for-
services, ages 18-64, non-dual enrolled, with HF diagnosis between July 1, 2005 to 
December 31, 2009, followed at least 3 months. Diagnosis for HF defined as 
earliest encounter claim that included ICD-9 code 428.xx. Comorbidity diagnoses 
determined between earliest claim and within three months post-HF diagnosis. 
The frequencies and cross-frequencies of the selected comorbidities are 
examined. RESULTS: Among 15,764 HF patients, 60% (n=9,388) were black, 33% 
(n=5,158) white, 6% (n=919) other, 2% (n=299) Hispanic. Over half were female 
(55%); 29% were ages 18-44, 36% ages 45-54, and 36% ages 55-64. The most 
common comorbidity was other cardiovascular disease (CVD, 78%), followed by 
hypertension (73%), psychological disorder (57%), chronic ischemic heart disease 
(43%), diabetes (41%), hyperlipidemia (37%), chronic obstructive pulmonary 
disease (28%), renal dysfunction (28%), and stroke (21%). This pattern persisted 
within any particular comorbidity group. Excluding hypertension and other CVD: 
10% of patients had zero comorbidities, 20% had only one, 70% had multiple 
comorbidities; 0.7% (n=114) had every comorbidity above. The median number of 
comorbidities was 2; median being 4 if hypertension and other CVD are included. 
CONCLUSIONS: An overwhelming majority of HF patients enrolled in Maryland 
Medicaid have multiple comorbidities. The prevalence of any comorbidity above 
was no less than 21%; the most prevalent comorbidities being hypertension, 
other CVD, and psychological disorder. Our findings call attention to the level 
comorbidity in a high-risk Medicaid population, reflecting a demographic largely 
under-represented in large scale studies or clinical trials. Future research should 
identify clinical and hospitalization issues associated with prevalent disease in 
this population.  
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DISEASE MODIFYING THERAPY AND THE RISK OF HOSPITALIZATION IN 
PATIENTS WITH HEART FAILURE: A CONTEMPORARY MEDICAID COHORT 
ANALYSIS  
Shaya FT1, Breunig IM1, Mehra MR2 
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Harvard Medical School, 
Boston, MA, USA  
OBJECTIVES: Increasing prevalence of heart failure (HF), increasing enrollment in 
state programs, sparse literatures on population-based heart failure studies, and 
the burden of hospitalization among Medicaid patients necessitate an analysis of 
risk factors for heart failure hospitalization in a contemporary Medicaid population. 
METHODS: Claims from Maryland State Medicaid, for 14,149 non-dually enrolled, 
18-64 year olds with a diagnosis for HF between 7/1/05-12/31/09, followed for at 
least six months. We examine the effects of comorbidity and first-line therapy use 
on the risk of any hospitalization after HF diagnosis. Multivariate Weighted Cox 
Regressions were used to address non-proportional risk of hospitalization over the 
follow-up period. We report numbers needed to treat with first-line therapy to 
prevent one hospitalization annually. RESULTS: Most patients were >45 years (71%), 
female (56%), and black (60%). Use prevalence was: beta-blockers (26%), ACE-
inhibitors/ARB (29%), aldosterone antagonists (AA, 5%), and others including 
nitrates+hydralazine (37%). Nearly all (98%) were diagnosed with one or more 
comorbidities. Relative risk (95% CI) for any hospitalization was 1.43 (1.36-1.51) renal 
dysfunction, 1.40 (1.31-1.50) other cardiovascular, 1.33 (1.26-1.40) COPD, 1.28 (1.22-
1.35) chronic ischemic heart disease, 1.27 (1.20-1.34) stroke, 1.26 (1.20-1.32) diabetes, 
1.11 (1.05-1.17) hypertension, 0.81 (0.77-0.85) hyperlipidemia, 0.77 (0.73-0.81) 
psychological disorder; 0.77 (0.73-0.81) ACE inhibitor/ARB, 0.83 (0.79-0.87) beta-
blocker, 0.76 (0.72-0.80) other cardiovascular drugs. AA and/or nitrates+hydralazine 
combination had no impact. The C-statistic for predicted 1-year hospitalization risk 
within the sample was 0.80. Numbers needed to treat to prevent one hospitalization 
annually: 12 ACE-inhibitor/ARB, 15 beta-blockers, or 11 other cardiovascular drugs. 
CONCLUSIONS: We elicit the specific risk attributable to lead risk factors in HF 
patients enrolled in Medicaid plans, and show certain disease modifying therapies 
can quantifiably mitigate risk of hospitalization. Growing ranks of state Medicaid 
plans and other entitlement programs call for more deliberate, proactive and cost-
effective disease and risk management of plan enrollees.  
 
PCV13  
RECURRENCE AND RISK FACTORS IN HOSPITALIZED PATIENTS WITH ACUTE 
VENOUS THROMBOEMBOLISM: A CLAIMS DATABASE ANALYSIS  
Xie L1, Liu X2, Phatak H3, Mardekian J2, Tan W2, Baser O4, Schneider RF2, Ramacciotti E3 
1STATinMED Research, Ann Arbor, MI, USA, 2Pfizer, Inc., New York, NY, USA, 3Bristol-Myers 
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OBJECTIVES: Venous thromboembolism (VTE) includes deep-vein thrombosis 
(DVT) and pulmonary embolism (PE), with a considerable risk of recurrence and 
mortality. This study examined the recurrence rate and associated risk factors in 
hospitalized patients with acute VTE in the US clinical practice setting. 
METHODS: Adult patients with VTE were selected from the linked MarketScan 
and Hospital Discharge database in an inpatient setting between 07/01/2006-
12/31/2011. The first hospitalization with a diagnosis of VTE (ICD-9-CM: 451-453, 
671.3, 671.4, 671.9, 415.1, 673.2, or 673.8) was designated as index hospitalization. 
Patients were required to have at least 6 months continuous enrollment and 
have no VTE diagnosis in the 6 months prior to index hospitalization. Patients 
were followed until the earliest of VTE recurrence, death, disenrollment, or the 
end of study. VTE recurrence was defined as re-hospitalization with VTE at least 
1 day after discharge from index hospitalization. Cox regression was used to 
model time to recurrence and examine demographic and clinical factors 
associated with recurrence. RESULTS: A total of 957 patients were eligible for the 
study, including 570 patients with DVT only (59.6%); 237 with PE only (24.7%); and 
150 with both DVT and PE (15.7%). Mean age was 62.8 years (SD=15.2), and 432 
were male (45.1%). Mean follow-up time was 23.1 months. During follow-up, 146 
patients recurred, with a recurrence rate of 15.3%. The average time to 
recurrence was 20.1 months (median=15.4). Number of comorbid conditions as 
measured by Charlson Comorbidity Index was independently associated with 
increased risk for VTE recurrence (hazard ratio [HR]: 1.12, 95%CI=1.05 – 1.20). 
CONCLUSIONS: More than 15% of hospitalized patients with acute VTE recurred 
during an average follow-up period of 23 months in the real clinical setting. 
Comorbidities were associated with increased risk for recurrence. Further 
research needs to examine recurrence and its economic outcomes associated 
with VTE treatment patterns.  
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IMPACT OF INITIATING STATIN THERAPY AT A HIGH DOSE – A RETROSPECTIVE 
OBSERVATIONAL STUDY POPULATIONS IN THE UNITED KINGDOM  
Chevalier P1, Lamotte M1, Rigney U2, Engstrom G3, Emmas C4 
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OBJECTIVES: High-dose statin therapy has been reported to be associated with 
increased risk of side effects, which may reduce treatment adherence and 
impact cardiovascular (CV) outcomes. This study assessed association between 
initial statin dose and treatment adherence and persistence and its impact on CV 
outcomes in the overall and sub-population with prior CV events. METHODS: An 
observational, retrospective study was conducted in a UK linked database (CPRD) 
comprising primary care, secondary care (Hospital Episode Statistics), and 
